Pacira BioSciences (PCRX) Capital Expenditures Growth (1y) (2011 - 2026)
Pacira BioSciences (PCRX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 32.28% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 3,566.67% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 113.56% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.95% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -21.54% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -59.55% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -84.04% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -76.65% |
| 10 | Pacira BioSciences | 940.31 Mn | 738.13 Mn | 140.96 Mn | -84.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.07% |
| Dec 31, 2025 | -233.52% |
| Sep 30, 2025 | 2,147.62% |
| Jun 30, 2025 | 220.83% |
| Mar 31, 2025 | 201.41% |
| Dec 31, 2024 | -25.35% |
| Sep 30, 2024 | 97.78% |
| Jun 30, 2024 | -165.57% |
| Mar 31, 2024 | -56.80% |
| Dec 31, 2023 | 149.29% |
| Sep 30, 2023 | -264.04% |
| Jun 30, 2023 | -70.99% |
| Mar 31, 2023 | -14.38% |
| Dec 31, 2022 | 118.39% |
| Sep 30, 2022 | -81.89% |
| Jun 30, 2022 | 335.78% |
| Mar 31, 2022 | -41.34% |
| Dec 31, 2021 | -111.78% |
| Sep 30, 2021 | 268.47% |
| Jun 30, 2021 | -138.18% |